New Ray Medicine International Holding Ltd. (HK:6108) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
New Ray Medicine International Holding Ltd. has announced that its subsidiary, Zhejiang Xinrui Biopharmaceutical, along with partners, will increase capital contributions to a total of RMB34 million for a healthy food industrial park project in Shengzhou, Zhejiang Province. This investment by Zhejiang Xinrui Biopharmaceutical, totaling approximately HK$14.59 million, will be classified as a financial asset at fair value, impacting the company’s profit and loss but not consolidating with its financial results. The deal, which adheres to the Listing Rules, signifies a notable expansion in the company’s project portfolio.
For further insights into HK:6108 stock, check out TipRanks’ Stock Analysis page.